Trial Profile
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Adenocarcinoma; Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms EXAM; ND
- Sponsors Exelixis
- 17 May 2021 Results assessing comparative effectiveness or efficacy of the single-arm LIBRETTO-001 (selpercatinib) trial with summary data from the EXAM trial (cabozantinib and placebo) in advanced/metastatic medullary thyroid cancer, presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 03 May 2020 Results (n=31) of a retrospective analysis evaluating prevalence and entity of proteinuria treated with cabozantinib in advanced and progressive MTC patients were published in the Journal of Endocrinological Investigation
- 22 Sep 2017 Results published in the Annals of Oncology